This story originally ran on April 7.
Seattle-based biotech firm VLST this week announced a collaboration with AnaptysBio for the generation of novel multi-antigen antibody therapeutics for autoimmune and inflammatory disorders.
VLST discovers and develops novel biologic therapeutics using an approach combining proteomics and bioinformatics.
Under the terms of the agreement, AnaptysBio will generate novel antibodies using its proprietary somatic hypermutation technology platform. VLST will develop and commercialize antibodies developed by AnaptysBio.
AnaptysBio has received an upfront payment and is eligible for certain milestone payments and royalties associated with the development and sale of products stemming from the collaboration, according to a joint statement from the two firms.
No further financial terms were disclosed.
According to VLST's website, the company has used its proteomics platform to identify multiple novel and "potentially druggable targets" for treating hepatitis C.
VLST also is developing a dimeric protein, VLST-007, comprised of human CD47 extracellular domain fused to the fragment crystallizable portion of a human IgG1 molecule. It has completed preclinical development of VLST-007 and is looking for a partner to further develop the product, it added.
Also in development is multikine antibody VLST-002 for autoimmune disorders and inflammatory diseases.
AnaptysBio, based in San Diego, develops therapeutic antibodies.